MyFinsight
Home
Blog
About
Proceeds from the
issuance of common stock,...
$49,567K
(279.39%↑ Y/Y)
Proceeds from the
issuance of common stock...
$861K
(28.70%↑ Y/Y)
Proceeds from the
issuance of common stock...
$26K
Net cash provided by
financing activities
$49,288K
(272.55%↑ Y/Y)
Canceled cashflow
$1,166K
Net increase
(decrease) in cash, cash...
-$85,727K
(-116.29%↓ Y/Y)
Canceled cashflow
$49,288K
Maturities of investments
$61,000K
(-32.22%↓ Y/Y)
Stock-based compensation
expense
$11,733K
(-21.48%↓ Y/Y)
Prepaid expenses, other
assets and long-term...
-$5,910K
(-185.81%↓ Y/Y)
Amortization of intangible
assets
$5,716K
(0.32%↑ Y/Y)
Depreciation and
amortization of property and...
$3,784K
(12.52%↑ Y/Y)
Excess and
obsolescence reserve
$3,314K
(-60.13%↓ Y/Y)
Amortization of right of use
asset
$902K
(-68.65%↓ Y/Y)
Loss on asset
disposals
-$642K
Unrealized foreign
exchange loss (gain)
-$3K
(-101.92%↓ Y/Y)
Tax payments
related to shares...
$1,166K
(131.35%↑ Y/Y)
Net cash provided by
(used in) investing...
-$74,050K
(-634.97%↓ Y/Y)
Net cash used in
operating activities
-$60,841K
(9.79%↑ Y/Y)
Canceled cashflow
$61,000K
Canceled cashflow
$32,004K
Effect of foreign
exchange rate changes
-$124K
(-116.78%↓ Y/Y)
Purchase of investments
$129,609K
(88.67%↑ Y/Y)
Net loss
-$47,315K
(57.63%↑ Y/Y)
Trade accounts
receivable
$20,361K
(285.10%↑ Y/Y)
Purchase of property and
equipment
$5,441K
(-27.07%↓ Y/Y)
Accounts payable
-$11,818K
(-1423.40%↓ Y/Y)
Accrued expenses and
other liabilities
-$8,615K
(-2965.84%↓ Y/Y)
Accretion of discounts and
premiums on investments
$1,413K
(-29.46%↓ Y/Y)
Deferred tax benefit
-$1,373K
(-169.06%↓ Y/Y)
Gain on loan
forgiveness
$1,000K
Operating lease
liabilities
-$773K
(68.79%↑ Y/Y)
Inventory
$177K
(102.55%↑ Y/Y)
Back
Back
Cash Flow
IOVA_BIG-svg
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVA_BIG-svg
source: myfinsight.com
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)